ArticleFrontiers in endocrinology2025
Sancai Lianmei granules ameliorate neuron injury in diabetic ischemic stroke rats by inhibiting oxidative stress and inflammation.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To assess the impact of Sancai Lianmei (SCLM) granules on diabetic ischemic stroke (IS) model rats, as well as oxygen and glucose deprivation (OGD)-induced PC12 neurons and lipopolysaccharide (LPS)-induced BV2 microglia, and to investigate the associated mechanisms. Methods: Initially, a diabetic IS model was established in rats through the intraperitoneal administration of niacinamide (NAA) in conjunction with streptozotocin (STZ), supplemented by thread embolization. The model rats were subsequently observed behaviorally, pathologically, and molecularly. Ultimately, the specific mechanism underlying SCLM was elucidated and validated through Results: SCLM improved neurological deficits and reduced infarct size in diabetic ischemic stroke models. Furthermore, SCLM modulated the expression of apoptosis-related proteins by downregulating p53 and Bax while upregulating Bcl-2. Additionally, SCLM inhibited the Toll-like receptor 4/nuclear factor kappa-B (TLR4/NF-κB) signaling pathway. Conclusion: The use of SCLM granules is a therapeutic strategy for alleviating oxidative stress and inflammation in diabetic ischemic stroke patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.